| # | Drug | Count |
|---|---|---|
| 0 | PREDNISONE | 128 |
| 1 | RITUXIMAB | 100 |
| 2 | METHOTREXATE SODIUM | 85 |
| 3 | METHOTREXATE | 78 |
| 4 | INFLIXIMAB | 76 |
| 5 | CYCLOPHOSPHAMIDE | 68 |
| 6 | CYCLOPHOSPHAMIDE FOR INJECTION | 68 |
| 7 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 68 |
| 8 | MYCOPHENOLATE MOFETIL | 67 |
| 9 | MYCOPHENOLATE MOFETIL HYDROCHLORIDE | 67 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | CHLORAMBUCIL | 28 | 0.0071 |
| 1 | PEGCETACOPLAN | 8 | 0.0042 |
| 2 | INFLIXIMAB-DYYB | 11 | 0.0032 |
| 3 | SUTIMLIMAB-JOME | 1 | 0.0031 |
| 4 | LONCASTUXIMAB TESIRINE | 1 | 0.0024 |
| 5 | ETRASIMOD | 4 | 0.0024 |
| 6 | BENDAMUSTINE HCL | 35 | 0.0022 |
| 7 | BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, AND TETRACYCLINE HYDROCHLORIDE | 2 | 0.0018 |
| 8 | VANCOMYCIN HYDROCHLORIDE | 12 | 0.0014 |
| 9 | IDELALISIB | 10 | 0.0014 |
| # | Drug class | Count |
|---|---|---|
| 0 | Corticosteroid [EPC] | 257 |
| 1 | CD20-directed Cytolytic Antibody [EPC] | 117 |
| 2 | Tumor Necrosis Factor Blocker [EPC] | 111 |
| 3 | Alkylating Drug [EPC] | 87 |
| 4 | Proton Pump Inhibitor [EPC] | 86 |
| 5 | Folate Analog Metabolic Inhibitor [EPC] | 80 |
| 6 | Nonsteroidal Anti-inflammatory Drug [EPC] | 75 |
| 7 | Kinase Inhibitor [EPC] | 70 |
| 8 | Integrin Receptor Antagonist [EPC] | 67 |
| 9 | Benzodiazepine [EPC] | 55 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Classical Complement Pathway Inhibitor [EPC] | 1 | 0.0031 |
| 1 | Interleukin-5 Antagonist [EPC] | 2 | 0.0029 |
| 2 | Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC] | 18 | 0.0008 |
| 3 | Integrin Receptor Antagonist [EPC] | 67 | 0.0008 |
| 4 | Nonergot Dopamine Agonist [EPC] | 11 | 0.0007 |
| 5 | CD19-directed Chimeric Antigen Receptor [EPC] | 6 | 0.0006 |
| 6 | SLAMF7-directed Immunostimulatory Antibody [EPC] | 3 | 0.0006 |
| 7 | Provitamin D2 Compound [EPC] | 16 | 0.0005 |
| 8 | Human Immunoglobulin G [EPC] | 11 | 0.0005 |
| 9 | Asparagine-specific Enzyme [EPC] | 7 | 0.0005 |